This company has been acquired
Tyme Technologies Past Earnings Performance
Past criteria checks 0/6
Key information
-6.90%
Earnings growth rate
5.40%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | n/a |
| Return on equity | -32.63% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger
Sep 15We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Aug 05
TYME stock surges on merger agreement and Syros Pharmaceuticals
Jul 05Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives
May 26We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Mar 19Tyme Technologies Offers Incredible Risk-Reward
Dec 07Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Nov 19Tyme Technologies: The Market Missed The Bullish Memo
Aug 27We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate
Jul 19Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Mar 26Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?
Feb 19
Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?
Feb 02Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?
Dec 16Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?
Dec 09Revenue & Expenses Breakdown
How Tyme Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -24 | 12 | 11 |
| 31 Mar 22 | 0 | -24 | 10 | 13 |
| 31 Dec 21 | 0 | -24 | 10 | 15 |
| 30 Sep 21 | 0 | -25 | 9 | 15 |
| 30 Jun 21 | 0 | -26 | 10 | 16 |
| 31 Mar 21 | 0 | -29 | 10 | 17 |
| 31 Dec 20 | 0 | -28 | 11 | 17 |
| 30 Sep 20 | 0 | -28 | 12 | 16 |
| 30 Jun 20 | 0 | -28 | 12 | 15 |
| 31 Mar 20 | 0 | -22 | 13 | 13 |
| 31 Dec 19 | 0 | -27 | 13 | 13 |
| 30 Sep 19 | 0 | -29 | 14 | 14 |
| 30 Jun 19 | 0 | -29 | 14 | 14 |
| 31 Mar 19 | 0 | -33 | 15 | 15 |
| 31 Dec 18 | 0 | -27 | 14 | 13 |
| 30 Sep 18 | 0 | -25 | 13 | 11 |
| 30 Jun 18 | 0 | -23 | 12 | 11 |
| 31 Mar 18 | 0 | -19 | 11 | 9 |
| 31 Dec 17 | 0 | -17 | 9 | 8 |
| 30 Sep 17 | 0 | -14 | 7 | 7 |
| 30 Jun 17 | 0 | -12 | 7 | 6 |
| 31 Mar 17 | 0 | -15 | 9 | 6 |
| 31 Dec 16 | 0 | -17 | 8 | 4 |
| 30 Jun 16 | 0 | -13 | 9 | 5 |
| 31 Mar 16 | 0 | -11 | 8 | 3 |
| 31 Dec 15 | 0 | -12 | 4 | 4 |
Quality Earnings: TYME is currently unprofitable.
Growing Profit Margin: TYME is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TYME is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.
Accelerating Growth: Unable to compare TYME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: TYME has a negative Return on Equity (-32.63%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/09/16 06:00 |
| End of Day Share Price | 2022/09/16 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tyme Technologies, Inc. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arlinda Lee | Canaccord Genuity |
| Joshua Schimmer | Evercore ISI |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |